Browse
Submit Data
Databases
API
Help

Dataset Information

7 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer

ABSTRACT: This pilot clinical trial studies cholecalciferol in treating patients with colorectal cancer. The use of cholecalciferol may slow disease progression in patients with colorectal cancer.

DISEASE(S): Adenocarcinoma,Rectal Neoplasms,Cystadenocarcinoma,Signet Ring Adenocarcinoma Of The Colon,Signet Ring Adenocarcinoma Of The Rectum,Stage I Colon Cancer,Adenocarcinoma, Mucinous,Stage I Rectal Cancer,Mucinous Adenocarcinoma Of The Colon,Mucinous Adenocarcinoma Of The Rectum

PROVIDER: 2110440 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Activated sludge from pilot-scale granular reactor treating WW

Project description:Activated sludge from pilot-scale reactor treating WW Metagenome

| PRJNA680224 | ENA

miRNA-seq of lungs tissue of swine supplemented with cholecalciferol and calcidiol

Project description:Results indicate that both increasing the dose of cholcalciferol and the use of calcidiol in the diet have a significant effect on lung tissue miRNAs compared to using the standard dose of cholecalciferol. The greatest changes in the transcriptome were induced by supplementation with the increased dose of the combination of cholecalciferol and calcidiol.

2023-11-23 | GSE217599 | GEO

Cholecalciferol and Calcium Carbonate in Treating Patients With Colon Cancer That Has Been Removed by Surgery

Project description:RATIONALE: The use of cholecalciferol and calcium carbonate may keep colon cancer from coming back in patients with colon cancer that has been removed by surgery. PURPOSE: This randomized clinical trial is studying two different doses of cholecalciferol to compare how well they work when given together with calcium carbonate in treating patients with colon cancer that has been removed by surgery.

| 2039759 | ecrin-mdr-crc

Real-time quantitative PCR analysis of human serum

Project description:open-label single-arm pilot phase II clinical trial of Regorafenib as a single agent in Frail Patients With Metastatic Colorectal Cancer. Blood samples for determination of serum miRNAs were taken on entry into the study and at the time of disease progression.

2021-12-14 | GSE155621 | GEO

Bioreactor treating sulfate wastewater

Project description:Bioreactor treating sulfate wastewater Metagenome

| PRJNA431585 | ENA

Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer

Project description:This phase II trial studies how well Polyphenon E works in treating patients with high-risk of colorectal cancer. Polyphenon E contains ingredients that may prevent or slow colorectal cancer.

| 2125933 | ecrin-mdr-crc

Long-term NAD+ supplementation prevents the progression of age-related hearing loss in mice

Project description:Age-related hearing loss (ARHL) is the most common sensory disabling condition associated with aging in humans. Yet, there are still no approved measures for preventing or treating this debilitating condition. With its slow progression, continuous and safe treatment approaches are critical for ARHL treatment. Nicotinamide Riboside (NR), a NAD+ precursor, is well-tolerated even for long-term use and is already shown effective in various disease models including Alzheimer’s and Parkinson’s Disease. However, its beneficial impact on ARHL is not known. In this study, we investigated transcriptomic profile in the cochlea of the mice (mtKeima strain) that are treated with NR for 10 months vs. non-treated.

2023-09-20 | GSE213994 | GEO

Effect of vitamin D on anxiety and depresion of patients with colorectal cancer

Project description:Intervention 1: The first intervention group: patients with a serum level of 25-hydroxyvitamin D3 less than 12 ng/ml receive 8 pearls of 50000 units of cholecalciferol from Zahravi Pharmaceutical Company one pearl weekly for 8 week and then 30 Tabs of 1000 units of cholecalciferol from Omid parsina damavand pharmaceuitical company, daily for 24 days. Intervention 2: The second intervention group: patients with a serum level of 25-hydroxyvitamin D3 of 12-20 ng/ml receive a total of 90 Tabs of 1000 units of cholecalciferol from Omid parsina damavand pharmaceuitical company, one pearl daily for 90 days. Intervention 3: The third intervention group: patients with a serum level of 25-hydroxyvitamin D3 of 20-30 ng/ml will receive a total of 60 pearls of 1000 units of cholecalciferol from Omid parsina damavand pharmaceuitical company accoriding to following command: Two days one pearl daily and then one day off for 3 months. Intervention 4: The fourth intervention group: patients with a serum level of 25-hydroxyvitamin D3 above 30 ng/ml will receive a total of 30 pearls of 1000 units of cholecalciferol from Omid parsina damavand pharmaceuitical company, one pearl every 3 days for 3 months. Primary outcome(s): Depression score in Zung questionnaire. Timepoint: Before starting intervention, 90 days after starting to take cholecalciferol. Method of measurement: Zung Self-Rating Depression Scale questionnaire.;Anxiety score in Zung questionnaire. Timepoint: Before starting intervention, 90 days after starting to take cholecalciferol. Method of measurement: Zung Self-Rating Depression Scale qestionnaire.;Serum level of 25-hydroxy vitamin D3. Timepoint: Before starting the intervention and 90 days after starting cholecalciferol. Method of measurement: enzyme-linked immunosorbent assay. Study Design: Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive.

| 24659 | ecrin-mdr-crc

Anaerobic biorreactor treating simulated textile effluent

Project description:Anaerobic biorreactor treating simulated textile effluent Metagenome

| PRJNA431584 | ENA

PLCO - Limited Use Pilot Test Data

Project description:PLCO - Limited Use Pilot Test Data

| PRJNA625585 | ENA